Production and Characterization of IgY against Canine IgG: Prospect of a New Tool for the Immunodiagnostic of Canine Diseases

Fernanda Nunes Santos1*, Beatriz Coutinho Brum1, Paula Borba Cruz2, Claudia Moraes Molinaro3, Valmir Laurentino Silva1 and Sérgio Augusto de Miranda Chaves4

1Departamento de Ciências Biológicas; Escola Nacional de Saúde Pública Sérgio Arouca; Fiocruz - Rio de Janeiro - RJ - Brasil. 2Instituto Oswaldo Cruz; Fiocruz; Rio de Janeiro - RJ - Brasil. 3Laboratório de Tecnologia Diagnóstica-Bio Manguinhos; Fiocruz; Rio de Janeiro - RJ - Brasil. 4Departamento de Endemias Samuel Pessoa; Escola Nacional de Saúde Pública Sérgio Arouca; Fiocruz; Rio de Janeiro - RJ - Brasil

ABSTRACT

This study describes the production of a new avian polyclonal antibody (IgY) against canine IgG, as another tool for the immunodiagnostic using IgY technology. The immunization protocol caused neither deaths nor pathologies, and no decline in egg laying capacity was detected. The total concentration of isolated IgY was constant, without significant difference (p> 0.05), with average of 97.55 mg of IgY/yolk. The IgY revealed a strong sensitivity and specificity in recognition against canine IgG by ELISA. After the immunization, there was a significant increase in the production of IgY specific from the first to the second month (p <0.05), reaching a stable peak without decrease in the production by the end of the analysis period (p> 0.05). The IgY demonstrated a suitable specificity in Western blot against the purified and serum canine IgG, not enabling recognition of canine IgM or IgG of other animal species. The specific IgY in the egg yolks of immunized hens proved to be a molecule with an appropriate purity and desired specificity against the immunizing antigen. Moreover, its constant production in large quantities during the four months analyzed indicated that IgY antibody production technology could be considered as an excellent alternative to the standard methods.

Key words: IgY polyclonal antibodies, chicken antibodies, hen immunization, canine IgG

INTRODUCTION

Antibody production against the canine Immunoglobulin G (IgG) is very important for the elaboration of diagnostic kits, which are intended to detect the serological markers of infection. Polyclonal antibodies from the mammals are extensively used for this purpose, involving the ethical issues due to invasive collection methods and euthanasia, as well as operational issues such as costly maintenance of the animal antibody donors and laborious purification methods usually resulting in low production yield (Leenaars et al. 1999). The antibody production should be performed in a manner imposing the least possible stress in the animals involved, combined with the maximum yield for long periods with a simple, efficient and economically viable purification process (Witkowski et al. 2009).

Chicken antibody production meets all these requirements, presenting itself as an alternative due to its benefits both in rendering the desired antibodies from the egg yolks and the simplified purification process (Hau et al. 2005). Like
mammals, birds transmit immunity to their offspring transferring immunoglobulins from the serum to the egg yolk (Kowalczyk et al. 1985). The most abundant immunoglobulin in chicken serum is IgY, which is transferred to and accumulated in great amounts in the egg yolk (Rose et al. 1974).

Immunoglobulin Y (IgY) is an excellent immunological reagent, presenting some beneficial features when compared to the mammalian IgG. Due to the phylogenetic distance between the birds and mammals, chickens are able to produce specific antibodies against highly conserved mammalian antigens, unlike rabbits, which are the typical source of antibody production. IgY binds neither to Fc receptors of mammals nor to the mammalian rheumatoid factor, as well as not activating the complement factor, features that reduce interpretation errors, or false positive results (Schade et al. 2000). The economic and operational advantages are related to their production, which is continuous and in large quantities throughout the laying period (Schade et al. 2000), about two years (Pauly et al. 2009). There are also ethical advantages, since the production does not require invasive collection methods, or euthanasia (Schade et al. 2000).

IgY can be applied in the same way as the mammalian IgG in immunodiagnostic tests (Schade et al. 2000). There are many studies describing IgY as an immunological reagent with appropriate sensitivity and specificity, revealing a performance equal, or superior to the mammalian immunoglobulins (Tini et al. 2002; Chalghoumi et al. 2009; Dias da Silva and Tambourgi 2010). Chicken antibodies can also be produced against many types of antigens and utilized in different methods and for different purposes (Narat 2003).

IgY was produced against immunoglobulins from different animal species, displaying excellent performance when compared with the mammal immunoglobulin (Bizanov et al. 2004; Kritratanasak et al. 2004; Nikbakht et al. 2009). It has also been successfully adopted in passive immunization of the dogs against parvovirus (Nguyen et al. 2006). Griot-Wenk et al. (1998), using recombinant proteins derived from the heavy chain of canine IgE, produced IgY capable of effectively recognizing canine IgE. In view of all these advantages and the absence of scientific reports regarding IgY against canine IgG on the immunodiagnosis of canine diseases, deeper studies related to the production and performance against the immunizing antigen are necessary and justified. This study describes IgY production against the canine IgG as a tool for the immunodiagnosis with IgY technology, emphasizing the evaluation of the immunization procedure, isolation, purification, characterization and the assessment of the specificity against the immunizing antigen and cross reaction presence.

**METODOLOGY**

**Experimental design**

Two Isa-Brown hens, 20-week-old, weighing 1.8Kg were used and maintained individually receiving the ration and drinkable water *ad libitum*. The experimental protocol was reviewed and approved by the Ethics Committee on the Use of Animals -CEUA-Fiocruz. License Number: LW-19/10.

**Immunization schedule**

For the immunization, 200 µg of ultrapurified canine IgG (Dog gamma-globulin ultrapurified Rockland-Inc) emulsified in 0.1mg/mL of Freund’s complete adjuvant was used. Two more inoculations in the same conditions were made using Freund’s incomplete adjuvant. The three inoculations were administered in the intervals of one week, intramuscular in the pectoral musculature with a final volume of 0.5 mL, distributed in various points. After an interval of 20 days from the last inoculation, the eggs were collected daily during four months and stored at 4-8°C. At the inoculation sites, the immunization adverse effects were observed by the palpation, tissue damage, or edema presence.

**IgY Isolation**

The isolation was carried out using the precipitation by PEG- Polyethylene glycol 6000 (Polson et al. 1980; Polson et al. 1985). The yolk was diluted 1:5 in the PBS (0.018M, pH 7.2), precipitated with 3.5% (w/v) of PEG and centrifuged at room temperature (RT) at 5000 xg. The supernatant was submitted to two more precipitations with 12% PEG. Then 2.5 mL of PBS at 0ºC and an equal volume of 50% absolute ethyl alcohol were added to the precipitate and centrifuged at room temperature (RT) at 5000 xg. The supernatant was submitted to two more precipitations with 12% PEG. Then 2.5 mL of PBS at 0ºC and an equal volume of 50% absolute ethyl alcohol were added to the precipitate and centrifuged at 10 000 xg for 25 min at -5°C. The precipitate was dissolved in 2.5 mL of PBS and frozen until the use. The IgY concentration in mg/mL was measured by spectrophotometry at
280 nm, according to Lambert-Beer law using an extinction coefficient of 1.33 (Leslie and Clem 1969).

**IgY Purification by affinity chromatography**

After the isolation, IgY was submitted to a purification process using thiofilic adsorption in Hitrap IgY purification column (GE, Healthcare). The sample and the column were submitted to a preparation procedure in accordance with the manufacturer instructions. A total of 100 mg of IgY was applied. A binding solution (20 mM NaH$_2$PO$_4$ and 0.5M K$_2$SO$_4$, pH 7.5) was used for the removal of non-bound material. Purified IgY was obtained using an elution solution (20 mM NaH$_2$PO$_4$, pH 7.5). To remove the non-bound material a cleaning solution (20 mM NaH$_2$PO$_4$, 30% isopropanol, pH 7.5) was used. The fractions containing IgY were separated through higher readings at 280 nm.

**IgY characterization by SDS-PAGE**

After the isolation and purification procedures, IgY was characterized by the SDS PAGE (Laemmli 1970). The IgY was diluted at 1:4 and examined in 10% SDS-PAGE under reduction conditions. The electrophoretic run was performed at 200 V for 80 min. For visualization, the Comassie Blue staining solution (0.4%) was used.

**Verification of IgY specificity by ELISA**

ELISA plates (Maxi Sorb, Nunc) were covered with different concentrations of canine IgG (3.9-0.007 µg/mL) in a carbonate bicarbonate buffer (20% 0.06 M Na$_2$CO$_3$ and 80% 0.06 M NaHCO$_3$, pH 9.6), and incubated at 4-8°C for 16 h. After two washings (PBS 0.05% Tween-20), different concentrations of purified IgY (56.4-0.3 µg/mL) were added in dilution solution (PBS 0.05% Tween-20 with 1% casein), followed by incubation at 37°C for 1 h. After three washings, anti-IgY conjugated to peroxidase developed in the rabbits (Promega Corporation, USA) in dilution solution 1:100 was added, followed by a new washing and incubation with secondary antibody (rabbit IgG anti-chicken IgY - Sigma-Aldrich, USA) in the concentration of 1:250 at 37°C for 1 h. Development was carried out using a developing solution (3.3 Diamine benzidine, 30% H$_2$O$_2$, 1% CoCl$_2$ in PBS) was used until the bands appeared. The reaction was stopped with distilled water.

**RESULTS AND DISCUSSION**

During the immunization process, the hens remained healthy without any abnormality in the development. No deaths occurred and all the animals presented normal behavior of the species. At the inoculation sites, there was neither pain nor discomfort, based on the reaction of the animal to palpation, or edema, and no tissue damage was evident. The brief manipulation time (five minutes per hen) of the immunization process afforded low stress levels and calm behavior during the procedures.

The absence of adverse effects for the immunization process could be explained due to the use of only three inoculations at different points, low volume of the inoculums and low stress levels from a short manipulation time. Furthermore, the Freund’s complete adjuvant (FCA) is directly responsible for the majority of
granulomatous lesions in inoculation sites (Bollen and Hau 1999), only in the first inoculation, replaced by Freund’s incomplete adjuvant (FIA), which causes a less adverse effect in subsequent immunizations. The absence of adverse effects has been described in many studies with chickens as antibody donors, even with different types of immunizing antigens (Levesque et al. 2007; Witkowski et al. 2009; de Paula et al. 2011). Contrastingly with the mammals, adverse effects and lesions are usually described in the immunization process (Leenaars et al. 1999).

In this study, there was no decline in egg laying capacity after the immunization process, which remained stable during four months, with an average of one egg per day. This has been described for chickens with respect to antibody production, since the chicken laying capacity is usually slightly affected by the antigen injection (Schade et al. 2005; Witkowski et al. 2009; de Paula et al. 2011; Matheis and Schade 2011). However, some studies have reported a reduction, or even an interruption in egg laying capacity for the chickens injected with toxic antigens (Schniering et al. 1996; Schade et al. 2005; Levesque et al. 2007), an occurrence not evident in the present study. Stress acts directly, decreasing the egg laying capacity and therefore, reducing IgY production (Shade et al. 2000; Schade et al. 2005). In this study, the immunization procedures involved low stress levels and absence of anesthesia, or invasive methods for the sample collection, usually associated with blood collection when mammals are recruited as antibody donors (Leenaars et al. 1999). Thus, the IgY production from the immunized chicken egg yolk was not in the least affected (Schade et al. 2000).

The adjuvant use in the immunization process can directly decrease the egg laying capacity (Schade et al. 2005). Usually, the most incriminated is the FCA (Bollen and Hau 1999). This was not observed in this study with FCA in association with FIA. In order to avoid the reduced egg laying capacity due to the immunization process, de Paula et al. (2011) immunized the chickens before the start of the laying period, the first inoculation being administered on the fourteenth day of life and the last, thirty days prior to the start of laying, and no decrease in laying capacity, or side effects due to the immunization process were detected (de Paula et al. 2011). In the present study, however, the first immunization was at twenty weeks of age, near the start of the laying period (approximately twenty-two weeks of age) and the remaining two weeks during the laying period, with laying capacity decrease neither during nor after the immunization process. The results demonstrated that the combination of the immunizing antigen to FCA and FIA generated neither laying decrease nor adverse effects, which indicate that this combination could be a good option for chicken immunization affording polyclonal antibody production.

In the samples extracted, the IgY yield showed concentrations from 14.28 to 65.48 mg/mL, with 39.02 mg/mL as an average. The volume of total IgY isolated from each egg was 2.5 mL, with an average of 97.55 mg of IgY/yolk. Considering the total concentration of specific IgY produced per inoculated antigen was up to 10% (Mine and Kovacs-Nolan 2002; Pauly et al. 2009), the maximum concentration of IgY producing an average of 9.75 mg specific IgY would be obtained from one egg yolk. Analyzing the concentration of isolated IgY of each egg yolk collected after the complete immunization, there was a constant profile during all the months, with no significant difference (Kruskal-wallis, H = 2.28, p > 0.05) and without oscillation during the period.

The successful production of polyclonal antibodies depends upon several factors related to immunization, one of them is related to the quality and quantity of the antigen used (Leenaars et al. 1999). This was followed in the present work, to immunize the chickens with IgG of high purity degree, avoiding the interference from the purification process of canine IgG from serum. The antigen amount seemed relevant to stimulate the immunological response, the ideal doses ranging from 10 µg to 1.0 mg (Schade et al. 2000). In this study, the vaccinal antigen concentration was within these ideal doses, previously determined according to results of Silva (1999). The adjuvant selection is another factor that directly plays a role in the production of high levels of yolk antibodies (Schade and Hlinak 1996) by promoting the cellular, humoral and immune memory (Schade et al. 2000), FCA being the most effective adjuvant to produce the antibodies in laboratory animals. Although it causes severe adverse effects in the mammals, it is most effective in the chickens, inducing high and sustained levels of yolk IgY (Schade et al. 2000). With respect to tissue damage caused by the FCA,
chickens are more resistant than the mammals (Schade et al. 2000), and the utilization of FIA as a replacement is effective (Chalghoumi et al. 2009). The FCA in the first immunization in combination with FIA in subsequent inoculations is preferable to prevent the adverse effects and yet induce high levels of IgY (Kapoor et al. 2000; Li et al. 2006; Chalghoumi et al. 2009).

Even though not all yolk contained IgY could be isolated by polyethylene glycol (PEG) (Stalberg and Larsson 2001), the results displayed a good level of IgY production, similar to the levels described with PEG precipitation in other studies (Pauly et al. 2009; de Paula et al. 2011). However, more efficient methods of purification have been reported (Akita and Nakai 1993; Stalberg and Larsson 2001; Bizanov et al. 2004), and the effectiveness of PEG precipitation is debatable. Different recovery rates ranging from 15 to 150 mg of IgY/egg have been established (Bizanov and Vyhniauskis 2000; Stalberg and Larsson 2001; Kitaguchi et al. 2008), which coincide with the IgY rates recovered in the present study with this method (97.55 mg of IgY/egg). Regarding IgG extracted from the rabbit blood, a maximum volume of 40 mL could be collected at four week intervals, involving the risk of death, corresponding to 20 mL of serum with approximately 12 mg/mL of IgG (Matheis and Schade 2011). According to this information, in a four month period using a rabbit, 960 mg of IgG in 160 mL of blood would be produced, involving the risk of death, corresponding to 20 mL of serum with approximately 12 mg/mL of IgG (Matheis and Schade 2011). According to this information, in a four month period using a rabbit, 960 mg of IgG in 160 mL of blood would be produced, while in this study, during this same period, one single chicken produced approximately two times that amount in IgY without invasive methods of collecting samples, or euthanasia. Even though more efficient methods have been described for IgY isolation (Akita and Nakai 1993; Stalberg and Larsson 2001; Bizanov et al. 2004), the precipitation method with PEG was chosen for isolating IgY with a high purity, low cost and ease of sample processing.

The production of isolated specific IgY after the immunization is shown in Figure 1, demonstrating a high level of immunoglobulin production twenty days after the complete immunization. There was a significant increase of IgY production from the first month after the immunization in relation to all the months analyzed (Kruskal-wallis test, H=17.86; p<0.05), with a production peak in the second month, stable until the end of the egg collection. There was no significant difference in IgY production during the last three months of egg collection, indicating that the antibody level remained constant, without presenting a drop in production during this entire period (Kruskal-wallis test, H=17.86; p>0.05).

The kinetics of chicken antibody production usually demonstrates a transitory increase titer after the first immunization, and in subsequent immunizations, there may be an initial increase with approximately 10 days, generating a plateau for another ten days and a decline thereafter (Schade et al. 2005). Different results were demonstrated in this study, since 20 days after the last immunization, there were high titers of specific IgY with a significant increase for the second month after the immunization (Kruskal-wallis test, H=17.86; p<0.05), after which there was a peak of production remaining stable for three months after the immunization (Kruskal-Wallis test, H = 17.86, p > 0.05). This confirmed that the immunization protocol was effective, resulting in high and stable levels of IgY until the fourth month after complete immunization without drop in antibody levels and without the need for subsequent immunizations during this period. Kritratanasak et al. (2004) obtained similar results, using FCA in the first immunization and FIA in the two subsequent ones in order to produce IgY against the mouse IgG. Twenty-one days after the complete immunization, a high level of immunoglobulin production was obtained, with peak production of two months after the complete immunization process, which remained stable until the fifty month, followed by a decline. However, different results were found by Bizanov and Jonauskiené (2003), which produced IgY...
against pig IgG with FCA in the first inoculation and FIA in the two subsequent ones, demonstrating an earlier peak production, than in this work, in the first month after the complete immunization process. However, there was also a decline in IgY production two months after the last pig IgG inoculation, in contrast to the present study (Bizanov and Jonauskiené 2003). The SDS-PAGE of IgY in reduction conditions is depicted in Figure 2A, line 1 indicating isolated IgY by the PEG. Various bands with different molecular weights could be seen, varying from 220-25 kDa. The heavy chain of IgY weighed 68 kDa and the light chain 27 kDa, the visualized accessory protein bands represented the impurities that were not fully eliminated in the isolation process, justifying a purification process by thiofilic adsorption. The SDS-PAGE of the purified IgY is shown in Figure 2B, line 1 displaying purified IgY with a similar previous profile, the IgY presenting a heavy chain with 68 kDa and the light chain with 27 kDa. The reduction of accessory bands could be visualized. However, the bands between 56.2 and 35.8 kDa were not eliminated even after the purification process.

Despite the consensus dispute about the molecular weight of IgY by most authors, the IgY was within agreement for the standard structure described (Warr et al. 1995; Schade and Hlinak 1996). There was a good result in the isolation process utilizing the PEG precipitation; however, with the presence of accessory proteins in small amounts representing the impurities not removed in this procedure. Because of this, a further purification process was justified for their removal, which directly interfered in the IgY recognition of the antigen for which it was produced, besides directly interfering in the process of conjugation with different types of enzymes and fluorochromes (Schade et al. 2000). The purification procedure resulted in a pure antibody, which could be verified removing most of said accessory protein bands without changing the electrophoretic profile after isolation. The presence of bands between 56.2 and 35.8 kDa, not removed after the purification procedure, has been described in other studies (Pauly et al. 2011; Matheis and Schade 2011), which probably corresponded to the C-terminal fragment of the vitellogenin II precursor (Klimentzou et al. 2006). These fragments encumbered IgY recognition neither of the immunizing antigen adopted in this study nor any of the previously described (Matheis and Schade 2011; Pauly et al. 2011).

The purified IgY reacted to the immunizing antigen until a 1:51200 dilution of 0.08 µg of IgY and a 1:40959 dilution of 0.05 µg of canine IgG.
revealing an excellent specificity of produced IgY against the immunizing antigen. These results showed the excellent recognition between IgY and IgG with the proclivity of linkage between both the immunoglobulins, even in the dilutions with lower concentrations of IgG and IgY, respectively. The production of IgY against the mouse IgG with FCA and FIA presented stable titers up to 1: 250,000 (Kritratanasak et al. 2004). Pauly et al. (2009) demonstrated in ELISA stable titers of up to 1000,000 IgY with FCA in the first and FIA in subsequent immunizations. Tu et al. (2006) with FCA in the first and FIA in subsequent immunizations produced an IgY with stable titers of 1.68 x 10^8, after the first injection until the sixteenth week. The developments of IgY titers in the present study were derived from only three immunizations, unlike the results described above with higher amounts of immunizing doses. Tu et al. (2006) used seven inoculations (one per week for seven weeks) and Pauly et al. (2009) used thirteen inoculations with an interval of four to eight weeks between them. However, Kritratanasak et al. (2004) applied three inoculations at intervals of two weeks each, resulting in superior IgY titers, compared to the present study (Kritratanasak et al. 2004).

In western blot (Fig. 3), line 9 demonstrated that the purified IgY was capable of specifically recognizing the purified canine IgG. The bands of 210 kDa to 29 kDa were evident, and both the heavy chain as well as the light chain were detected. Similarly, this antibody also recognized IgG of serum from a Leishmania (Leishmania) chagasi infected dog (line 8). The purified IgY did not recognize IgG of other animal species such as cat IgG (line 6), guinea pig IgG (line 5), rabbit IgG (line 4), goat IgG (line 3), sheep IgG (line 2) or horse IgG (line 1). Furthermore, no recognition was detected for dog IgM (line 7).

In the western blot, the purified IgY was able to recognize effectively and specifically both the specific IgG canine used as immunizing antigen, as present in the serum of infected dog, due to IgY ability to recognize the epitopes more effectively when mammalian proteins were used with the antigens (Svendsen et al. 1996). There was no binding of IgY to other animal species immunoglobulins, a characteristic usually described in the mammal antibodies, which have cross reactivity with different immunoglobulins species (Dias da Silva and Tambourgi 2010).

Similar results were found in this study, in which the IgY was able to recognize the immunizing antigen specificity, were common in the literature (Gassmann et al. 1990; Tini et al. 2002; de Paula et al. 2011). However, different results were described by Nikbakht et al. (2009) when they produced an IgY against the camel IgG. They obtained strong western-blot recognition against the heavy and light chain of camel serum IgG. However, the IgY produced was capable of also recognizing the IgG heavy chain of bovine, horse and sheep serum, indicating that this IgY was produced with the different epitopes of the IgG of these other species in western blot analysis (Nikbakht et al. 2009). The results in this work showed the excellent potential of produced IgY as an immunological reagent, which could be used as a capture antibody, or conjugate in the kits for the immunological diagnosis of different canine diseases.

CONCLUSIONS

The production of polyclonal antibodies through the chicken immunization proved to be an excellent alternative, producing the antibodies in large amount and quality from the simple methods of production without the need for invasive
collection methods, able to recognize both serum IgG from the infected dog and purified IgG used with antigen with effectiveness without cross-reactivity with other species immunoglobulins and isotypes. Hence, it presented itself as an excellent tool for detecting the specific antibodies, which might be adopted as efficient immunological reagent for canine diagnosis of different diseases.

ACKNOWLEDGMENT


REFERENCES


Hau J, Hendriksen CF. Refinement of polyclonal antibody production by combining oral immunization of chickens with harvest of antibodies from the egg yolk. ILAR J. 2005; 46 (3):294-299.


Levesque S, Martinez G, Fairbrother JMPS. Improvement of adjuvant systems to obtain a cost-effective production of high levels of specific IgY. Poult Sci. 2007; 86 (4): 630-635.


Received: May 23, 2013; Accepted: October 16, 2013.